Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
Decitabine for injection - Accord Healthcare 50 mg single-dose vial
Product / population
Single-agent IV decitabine for labeled MDS regimens; not oral decitabine/cedazuridine (INQOVI). Exact preparation remains product-specific.
Renal measure
Serum creatinine in mg/dL; no clearance equation attached to the toxicity trigger
Before using this finding
Separate pre-existing renal evidence gaps from new toxicity, blood-count recovery and exact IV product instructions.
Selected named sections only; not a complete monograph or independent clinical approval.
Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.
Renal dosing, restrictions and evidence limits
The Accord IV label states that pre-existing renal impairment was not studied; weigh treatment risks and benefits. Obtain baseline serum creatinine, CBC/platelets and hepatic testing. Delay subsequent treatment for serum creatinine >=2 mg/dL and do not resume until the toxicity resolves. Hematologic toxicity, infection and hepatic criteria remain separate. This is a subsequent-cycle toxicity instruction, not evidence for a renal dose calculation or an oral INQOVI substitution.
Source revision: 9/2023 | Retrieved: 2026-09-10. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
Decitabine for injection - Accord Healthcare 50 mg single-dose vial
Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release
No dialysis regimen established in selected content
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
toxicity trigger versus renal dose band
A serum-creatinine cycle-hold trigger is not a clearance cutoff
Selected IV sources agree on unstudied pre-existing renal impairment and a subsequent-cycle toxicity hold at serum creatinine >=2 mg/dL.
How to use this: Do not derive a CrCl threshold or transfer this instruction to oral decitabine/cedazuridine.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
Decitabine for injection - Accord Healthcare 50 mg single-dose vial
Single-agent IV decitabine for labeled MDS regimens; not oral decitabine/cedazuridine (INQOVI). Exact preparation remains product-specific.
Method: Serum creatinine in mg/dL; no clearance equation attached to the toxicity trigger
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
DailyMed / Accord Healthcare Inc. · Single-agent IV decitabine for labeled MDS regimens; not oral decitabine/cedazuridine (INQOVI). Exact preparation remains product-specific.
Renal method: Serum creatinine in mg/dL; no clearance equation attached to the toxicity trigger Source date: 9/2023 Retrieved: 2026-09-10
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding
Separate pre-existing renal evidence gaps from new toxicity, blood-count recovery and exact IV product instructions.
Dialysis evidence: No dialysis regimen established in selected content
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The Accord IV label states that pre-existing renal impairment was not studied; weigh treatment risks and benefits. Obtain baseline serum creatinine, CBC/platelets and hepatic testing. Delay subsequent treatment for serum creatinine >=2 mg/dL and do not resume until the toxicity resolves. Hematologic toxicity, infection and hepatic criteria remain separate. This is a subsequent-cycle toxicity instruction, not evidence for a renal dose calculation or an oral INQOVI substitution.
Selected named sections only; not a complete monograph or independent clinical approval.
Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.
GlobalRPh-hosted RX List · Single-agent IV decitabine for labeled MDS regimens; not oral decitabine/cedazuridine (INQOVI). Exact preparation remains product-specific.
Renal method: Serum creatinine in mg/dL for treatment-emergent toxicity; no derived eGFR cutoff Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-10
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding
Apply the toxicity hold in its cycle context; do not translate serum creatinine 2 mg/dL into a universal renal-function threshold.
Dialysis evidence: No dialysis regimen established in selected content
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Pre-existing renal impairment was not studied in the mirror; evaluate risks and benefits before treatment. Its nonhematologic-toxicity instructions delay subsequent treatment at serum creatinine >=2 mg/dL until toxicity resolves. This serum-creatinine trigger is not a CrCl threshold, an initiation eligibility rule or a numerical renal-dose ladder. Hematologic recovery and other toxicity criteria are separately applicable. No dialysis supplement is established by the selected paragraphs.
Selected named sections only; not a complete monograph or independent clinical approval.
A label mirror is not independent corroboration of its underlying label. See the separately attributed official source; concordance is limited to selected sections.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.